Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s traded shares stood at 0.88 million during the last session, with the company’s beta value hitting 1.41. At the close of trading, the stock’s price was $12.85, to imply an increase of 5.33% or $0.65 in intraday trading. The CNTA share’s 52-week high remains $13.56, putting it -5.53% down since that peak but still an impressive 59.92% since price per share fell to its 52-week low of $5.15. The company has a valuation of $1.45B, with an average of 0.44 million shares in intraday trading volume over the past 10 days and average of 275.82K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Centessa Pharmaceuticals plc ADR (CNTA), translating to a mean rating of 1.29. Of 6 analyst(s) looking at the stock, 0 analyst(s) give CNTA a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.42.

Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) trade information

After registering a 5.33% upside in the last session, Centessa Pharmaceuticals plc ADR (CNTA) has traded red over the past five days. The 5-day price performance for the stock is 2.80%, and 24.88% over 30 days. With these gigs, the year-to-date price performance is 61.43%. Short interest in Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA) saw shorts transact 1.38 million shares and set a 5.21 days time to cover.

The extremes give us $15 and $15 for target low and target high price respectively. As such, CNTA has been trading -16.73% off suggested target high and -16.73% from its likely low.

Centessa Pharmaceuticals plc ADR (CNTA) estimates and forecasts

Looking at statistics comparing Centessa Pharmaceuticals plc ADR share performance against respective industry, we note that the company has underperformed competitors. Centessa Pharmaceuticals plc ADR (CNTA) shares are 16.71% up over the last 6 months, with its year-to-date growth rate lower than industry average at -2.55% against 19.70%. Revenue is forecast to shrink -5.00% this quarter before falling -18.40% for the next one.

CNTA Dividends

Centessa Pharmaceuticals plc ADR has its next earnings report out on 2024-Aug-13. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Centessa Pharmaceuticals plc ADR (NASDAQ:CNTA)’s Major holders

Centessa Pharmaceuticals plc ADR insiders hold 1.84% of total outstanding shares, with institutional holders owning 87.90% of the shares at 89.54% float percentage. In total, 87.90% institutions holds shares in the company, led by MEDICXI VENTURES MANAGEMENT (JERSEY) LTD. As of 2024-06-30, the company held over 19.96 million shares (or 19.9856% of shares), all amounting to roughly $180.27 million.

The next major institution holding the largest number of shares is GENERAL ATLANTIC, L.P. with 9.68 million shares, or about 9.6927% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $87.43 million.

We also have Fidelity Select Portfolios – Biotechnology and Price (T.Rowe) Health Sciences Fund as the top two Mutual Funds with the largest holdings of the Centessa Pharmaceuticals plc ADR (CNTA) shares. Going by data provided on Jun 30, 2024 , Fidelity Select Portfolios – Biotechnology holds roughly 2.79 shares. This is just over 2.46% of the total shares, with a market valuation of $35.82 million. Data from the same date shows that the other fund manager holds a little less at 1.48, or 1.31% of the shares, all valued at about 19.02 million.